PharmiWeb.com - Global Pharma News & Resources
30-Jan-2020

Vetter Aligns its Development Service Laboratory Portfolio Under One Roof

  • Bundling of competencies optimizes workflow of customer projects
  • Further expansion of laboratory space to continue through 2020
  • Company continues to invest strongly in its future

RAVENSBURG, Germany, January 30, 2020 / B3C newswire / -- Vetter, a global operating Contract Development and Manufacturing Organization (CDMO) has brought together its development laboratories in one Ravensburg site end of last year. Designed to improve workflow and enhance customer benefits within the daily support in complex development projects, the services at the 1,800 sqm building include process development as well as functional and specification testing of packaging systems, chemical-analytical and biochemical analysis and particle characterization. State-of-the-art non-GMP laboratory space and equipment combined with a leading-edge GMP analytical laboratory now allow for increased capacity and optimized work spaces.

At present, more than fifty employees work in the new labs. By bringing the laboratories under one roof, employees easily share expertise and know-how to improve and simplify information exchange, leverage synergies and reinforce an overall positive work atmosphere. Overall customer will benefit from the alignment. Prior to the bundling of its laboratories, the development studies and the corresponding analytical services for testing during process or packaging material development took place in several labs at different locations in Ravensburg and Langenargen. By sequencing these services, processes have been synchronized and handling issues reduced, all leading to numerous benefits primarily for customer projects, but also for projects undertaken within the company.

“Our customers are excited and impressed with the new and modern development laboratories and their increased capacity. Now they can follow a complete development process and its individual steps, since it proceeds throughout the labs, all within the same building,” said Dr. Claus Feussner, Senior Vice President Development Service. Expansion will continue within the building throughout the year and includes still more lab space and the provision of additional innovative analytical equipment and lyophilizer capacity.

Vetter is also committed to further process optimization and capacity expansion in filling and secondary packaging of injectables at all its sites. This is based on increased global customer demand for the development and commercialization of promising new compounds.

 

Caption: Modern laboratory environment in the new 1,800 sqm building.
Picture source: Vetter Pharma International GmbH 
For high resolution please click the image.

Find the Vetter press kit and more background information here.  

 

About Vetter
Headquartered in Ravensburg, Germany, Vetter is a global leading contract development and manufacturing organization (CDMO) with production facilities in Germany and the United States. Currently employing 4,900 individuals worldwide, the company has long-term experience in supporting biotechnology and pharmaceutical customers both large and small. Vetter services range from early stage development support including clinical manufacturing, to commercial supply and numerous packaging solutions for vials, syringes and cartridges. As a leading solution provider, Vetter appreciates its responsibility to support the needs of its customers by developing devices that contribute to increased patient safety, convenience, and enhanced compliance. Great importance is also given to social responsibility including environmental protection and sustainability.

 

Contact

Vetter Pharma International GmbH
Markus Kirchner
Corporate Spokesperson / Media Relations
Eywiesenstrasse 5
88212 Ravensburg
Germany
+49 (0)751-3700-3729
PRnews@vetter-pharma.com

 

Keywords: Humans; Syringes; Pharmaceutical Services; Biotechnology; Pharmaceutical Preparations; Laboratories; Drug Packaging; Product Packaging

 

Published by B3C newswire and shared through Newronic®

Editor Details

Last Updated: 30-Jan-2020